1
Participants
Start Date
January 31, 2014
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2017
EBV CTL's
Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
Peripheral Blood Donor
Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
New York Medical College, Valhalla
Children's National Medical Center, Washington D.C.
Lead Sponsor
Collaborators (1)
Children's National Research Institute
OTHER
Baylor College of Medicine
OTHER
M.D. Anderson Cancer Center
OTHER
University of Michigan
OTHER
University of Utah
OTHER
City of Hope Medical Center
OTHER
Ohio University
OTHER
Johns Hopkins University
OTHER
New York Medical College
OTHER